Compulsory License Policy
- All
- News
-
Top American Business Group Seeks Clarity In India's Compulsory License Policy
Top American business advocacy group USIBC has sought transparency, consistency and clarity in the compulsory license policy of the Indian government in a bid to attract investments that are "imperative" for innovation.
-
Cipla Seeks Adoption of Pragmatic Intellectual Property Rights Policy
Many countries such as Brazil, Thailand, Indonesia and Malaysia have already introduced compulsory licensing provisions. India must also examine the monopoly position of drugs and build safeguards to ensure that this does not happen. India has always stood for the promotion of knowledge and consideration for the greater good, Mr Hamied said.
-
New drug policy, regulations slowing down pharma growth: report
The pharma industry is also witnessing challenges like delays in clinical trial approvals, uncertainties over the FDI policy, a uniform code for sales and marketing practices and compulsory licensing, according to the report by CII-PwC.
-
*Cipla head seeks pragmatic compulsory licensing policy
MUMBAI, AUGUST 25Phone: +91 (22) 6147 5100. feedback@tickerplantindia.com Copyright (c) TickerPlant Ltd.Copyright (c) TickerPlant Ltd.
-
Top American Business Group Seeks Clarity In India's Compulsory License Policy
Top American business advocacy group USIBC has sought transparency, consistency and clarity in the compulsory license policy of the Indian government in a bid to attract investments that are "imperative" for innovation.
-
Cipla Seeks Adoption of Pragmatic Intellectual Property Rights Policy
Many countries such as Brazil, Thailand, Indonesia and Malaysia have already introduced compulsory licensing provisions. India must also examine the monopoly position of drugs and build safeguards to ensure that this does not happen. India has always stood for the promotion of knowledge and consideration for the greater good, Mr Hamied said.
-
New drug policy, regulations slowing down pharma growth: report
The pharma industry is also witnessing challenges like delays in clinical trial approvals, uncertainties over the FDI policy, a uniform code for sales and marketing practices and compulsory licensing, according to the report by CII-PwC.
-
*Cipla head seeks pragmatic compulsory licensing policy
MUMBAI, AUGUST 25Phone: +91 (22) 6147 5100. feedback@tickerplantindia.com Copyright (c) TickerPlant Ltd.Copyright (c) TickerPlant Ltd.
